Diabetes

Advance of disease driven by high BMI, with social determinants of health playing a role

Endocrinologists urged to pay attention to COORDINATE trial

Once-weekly CagriSema reduced body weight more than either agent alone

Another study showed two high doses were better at reducing HbA1c vs a 14-mg dose

Plus, two other studies on retatrutide show benefit in type 2 diabetes, fatty liver disease

More positive results in CLEAR Outcomes sub-analysis

Superior to once-a-day insulin glargine U100 and degludec

Daily orforglipron also lowered HbA1c in type 2 diabetes

Phase IIb ENLIVEN trial saw success with various doses of pegozafermin

Now another oral option other than metformin

Researcher warns of "alarm fatigue" if thresholds aren't optimized to patient

Effects in small study seen independent of weight loss

Study findings highlight the importance of prioritizing eye care, diabetic retinopathy screening

Indirect medical expenses, diabetic alert dogs among top fundraising requests